Acta Dermato-Venereologica Suppl 219 AbstractPsoriasis2018 | Page 5

List of Abstracts 048 049 050 051 052 053 054 055 056 057 058 059 060 061 062 063 064 065 066 067 068 070 071 073 074 075 076 077 078 079 080 081 082 083 084 085 086 088 089 090 091 092 093 094 095 096 098 099 100 101 102 3 Predictors of Response to Tildrakizumab for Moderate to Severe Chronic Plaque Psoriasis Long-term efficacy of guselkumab treatment after drug withdrawal and retreatment in patients with moderate-severe plaque psoriasis: results from VOYAGE 2 Outcomes Associated with Achievement of Various Treatment Targets in Patients With Psoriatic Arthritis Receiving Adalimumab Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: Three Year Results from a Phase 3 Study (SPIRIT-P1) Incidence of Serious Gastrointestinal Events Among Tildrakizumab-Treated Patients With Psoriasis Durable Reduction in Absolute PASI with Certolizumab Pegol in Patients with Chronic Plaque Psoriasis Relationships Between Tildrakizumab Dose, Exposure, Efficacy and Safety in Psoriasis Phase 3 Studies Long-Term Safety and Efficacy of Adalimumab from the Phase 3 Randomized, Placebo-Controlled Trial in Patients with Nail and Skin Psoriasis Eight-Year Interim Results from the ESPRIT 10-Year Postmarketing Surveillance Registry of Adalimumab for Moderate to Severe Psoriasis Durability of Response in Certolizumab Pegol-Treated Patients over 48 Weeks in CIMPASI-1 & 2 Trials Primary Efficacy and Safety of Adalimumab in Nail Psoriasis From the First 26 Weeks of a Phase-3, Randomized, Placebo-Controlled Trial With Subanalysis in Patients With and Without Psoriatic Arthritis Certolizumab Pegol Is Effective for Chronic Plaque Psoriasis Across Patient Subgroups Discontinuation of Biologic Therapies in Chronic Plaque Psoriasis: A Retrospective Cohort Incidence of Infections in Clinical Trials of Tildrakizumab for Moderate to Severe Plaque Psoriasis Efficacy and Safety of Risankizumab: Results from Two Double-Blind, Placebo- and Ustekinumab-Controlled, Phase 3 Trials in Moderate- to-Severe Plaque Psoriasis Efficacy and safety of guselkumab administered with a novel self-injection device for the treatment of moderate-to-severe psoriasis: Results from the Phase III ORION self-dose study through Week 16 Efficacy of Tildrakizumab in Etanercept Partial Responders or Nonresponders Efficacy of Tildrakizumab in Moderate to Severe Psoriasis Patients With Prior Exposure to Apremilast Risankizumab Efficacy/Safety in Moderate-to-Severe Plaque Psoriasis: 16-Week Results from IMMhance Disease Severity and Efficacy Insights: Patient-Level PASI Scores in Tildrakizumab Psoriasis Trials Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis Better Skin Clearance is Associated with Improved Quality of Life in Moderate-to-Severe Psoriasis Patients Treated with Tildrakizumab Statistic review of psoriasis systematic therapies in North Greece Pharmakovigilance of systemic antipsoritic drugs: an update from routine care The Impact of Patient Requests on Psoriatic Arthritis Treatment Epidemiology The Risk Of KC In Psoriasis Patients Receiving Biologics Compared To Conventional Systemic Therapies Patient perceptions of psoriasis severity in Sweden, Norway, and Denmark Patient expectations and satisfaction in psoriasis treatment: A survey from Europe and Canada Socioeconomic determinants of paediatric psoriasis Obesity and the risk of psoriasis: A Korean nationwide, population-based study Clinical characterization of Psoriatic Arthritis in a multidisciplinary care model of patients with Psoriasis Triggering factors in childhood psoriasis Quality of care for psoriasis in the past 12 years – results from a series of nationwide health care studies in Germany Global Psoriasis Atlas – Work Stream 2 Global Burden of Disease: A Systematic Literature Review on Disability Weights for Skin Diseases Genetics MIR-499 polymorphism is associated with susceptibility to psoriatic arthritis – preliminary study Association between inflammasome-related polymorphisms and clinical phenotypes of Psoriatic arthritis Health Economics and Health Policies Frequency of Inadequate Response to Treatment among Psoriasis Patients on First-Line Biologics Barriers of guideline-compliant care for psoriasis in Germany – Results of the European study PsoBarrier Interesting Clinical Cases Individualised Therapy for Psoriasis - Case series A Unique Clinical Case of Psoriatic Arthritis and Relapsing Polychondritis Spiny follicular hyperkeratosis in a psoriasis patient treated with ustekinumab Combination therapy of apremilast and biological product in a patient with psoriasis. Psoriasis worst-case scenarios: A series of 3 case reports Successful switching to biosimilar in psoriatic patient with severe drug reaction to infliximab. A case report Safety of Apremilast in the treatment of a psoriasis patient with chronic Hepatitis B Pathophysiology and immunobiology IL-22 induces keratinocytes hyperproliferation in psoriasis via miR-21 and miR-31 upregulation Serum concentra cion of IFN-gamma in patients with psoriasis: correlation with clinical type and severity of disease Immunological memory exists in the recurrent lesion and nonrecurrent skin after remission in psoriatic patients Investigating systemic inflammation as the common link between depression, Psoriasis, and Psoriatic arthritis in US Veterans. The Immune-phenotype of Small Plaque Psoriasis Acta Derm Venereol 2018